AP NEWS
Click to copy
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Nemaura Medical to Hold a Symposia at EASD in Barcelona on Thursday September 19, 2019

September 12, 2019

Loughborough, England , Sept. 12, 2019 (GLOBE NEWSWIRE) -- Loughborough, England – September 12, 2019 – Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced that Dr. Faz Chowdhury, Chief Executive Officer, Dr. Fred Schaebsdau, VP Strategic Alliances, and Dr Iain Cranson, a diabetes specialist based in the UK, will be presenting at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) on Thursday, September 19, 2019 at 18:45 - 20:15 Central European Time at the Fira Barcelona Gran Via (Maimonides Hall) in Barcelona, Spain. The evening symposia will focus on the historic development of SugarBEAT®, its application to all categories of diabetics and diabetes management, clinical data and recent user experiences. The presentation is titled: “SugarBEAT® Non-Invasive CGM User Study Results: Diagnostic and Monitoring Applications Across Different Patient Types and Clinical Settings.”

Dr. Faz Chowdhury, CEO of Nemaura commented, “We are very pleased to be holding this symposia at this premier industry conference. We will be reporting study results from our first users, as well as sharing prior clinical data and user experiences. We also plan to discuss our commercial launch plans, including product availability in different territories. We look forward to highlighting how SugarBEAT® differs from current invasive CGM technologies and the potential to expand the addressable market to include Type 2 diabetics and pre-diabetics.”

The EASD Annual Meeting is Europe’s largest and most prominent meeting on diabetes. The 55th Annual Meeting will be held September 16-20, 2019 at the Fira Barcelona Gran Via, Spain. The scientific program offers researchers and healthcare professionals the opportunity to share ideas and learn about cutting-edge research and technology, groundbreaking studies and the significant advances in diabetes research, treatment and care. Additional information is available at: https://www.easd-industry.com

About Nemaura Medical, Inc.:

Nemaura Medical, Inc. (NASDAQ: NMRD), is a medical technology company commercializing SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) designed to help people with diabetes and pre-diabetics better manage their glucose levels by spending more time in range. Insulin users can adjunctively use SugarBEAT® when calibrated by a finger stick reading. SugarBEAT® consists of a daily, disposable adhesive skin-patch connected to a small form factor rechargeable transmitter, connected via Bluetooth to a specially designed mobile application, which displays glucose readings at five-minute intervals throughout the day.

For more information visit:

www.NemauraMedical.com

www.SugarBEAT.com

Cautionary Statement Regarding Forward-Looking Statements:

The statements in this press release that are not historical facts, and may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Nemaura’s ongoing studies, including the safety and efficacy of Nemaura’s SugarBEAT® system, the failure of future development and preliminary marketing efforts, Nemaura’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Nemaura and its partners’ ability to develop, market and sell SugarBEAT®, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to SugarBEAT®. These and other risks and uncertainties are identified and described in more detail in Nemaura’s filings with the United States Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the most recently completed fiscal year, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Nemaura undertakes no obligation to publicly update or revise any forward-looking statements.

Contact: Crescendo Communications, LLC 212-671-1021 NMRD@crescendo-ir.com

All contents © copyright 2019 The Associated Press. All rights reserved.